Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 DeFi Kingdoms DeFi Kingdoms +1,091.68%
#4 Black Phoenix Black Phoenix +336.08%
#5 aPriori aPriori +112.62%
#6 Bedrock Bedrock +74.62%
#7 Cysic Cysic +47.27%
#8 Prom Prom +41.40%
#9 Playnance Playnance +34.98%
#10 COTI COTI +31.11%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Poniard Pharmaceuticals, Inc. Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals, Inc.

PARD
Rank in Stocks #42764
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the... Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$150.00
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Poniard Pharmaceuticals, Inc. (PARD)

Category

Healthcare
Revenue for Poniard Pharmaceuticals, Inc. (PARD)
Revenue in Aug 2026 TTM: 0
According to Poniard Pharmaceuticals, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Poniard Pharmaceuticals, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR